Satellos Bioscience Taps Antoinette Paone as Chief Development Officer

Satellos Bioscience Inc., a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, has appointed Antoinette Paone as Chief Development Officer (CDO) and Head of Regulatory Affairs.

Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals. She joins Satellos from Generation Bio, where she most recently served as Chief Operating Officer.

“Bringing Ms. Paone on board to the executive team is incredibly exciting given her track record of charting the path to regulatory approval for breakthrough medicines,” said Frank Gleeson, Satellos co-founder and CEO. “With our two clinical studies in DMD advancing in adult and pediatric populations, the possibility of pursuing regulatory approval for SAT-3247 in the future is beginning to come into view. The appointment of Ms. Paone is not only timely, but also reflects our confidence in our expanding set of clinical data.”

Experience

At Generation Bio, Paone led the company’s growth from start-up to a development-ready organization, shaping key business functions, including regulatory strategy, quality, CMC, technical operations, and program management. She was also part of the executive team responsible for a series of equity financings over four years, including a successful IPO and a strategic partnership with Moderna.

Prior to Generation Bio, she spent more than a decade at Vertex, most recently as Vice President, Head of North American Regulatory Affairs Strategy, where she led regulatory efforts for multiple novel small molecule cystic fibrosis therapies. Earlier in her career, she held roles at Merck & Co. and Millenium Pharmaceuticals, Inc.

Paone holds an MBA from Bentley College, an MS in Organic Chemistry from Yale University, and a BS in Chemistry from Fordham University.

“I feel so fortunate to join Satellos in its bold mission to change what is possible in the treatment of Duchenne muscular dystrophy and other serious and life-limiting muscle diseases with great unmet need,” said Paone. “Having long-been focused during my career on bringing transformative medicines to people living with devastating diseases, I am eager to bring my perspective to Satellos as we work together to cultivate a roadmap for success.”